Picture used for representational functions solely.
| Photograph Credit score: The Hindu
The Maharashtra Meals and Drug Administration has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd’s Carry and Forwarding (C&F) unit in Pune over severe irregularities associated to the packaging, storage and recall of Reactin Plus Tablets, the regulator stated.
The FDA stated in an announcement issued on Friday (August 28, 2026) that the cancellation got here into impact on August 27, following an inspection of its major warehouse at Wadki in Pune district.
The regulator had discovered that medicines had been saved straight on the ground and flagged deficiencies in procedures for dealing with expired medicines.
Throughout an inspection round June this 12 months, officers discovered that the packaging of Reactin Plus tablets, a Schedule H prescription drugs, carried an unauthorised declare describing it as an “analgesic and antipyretic”, the assertion stated.
The FDA seized inventory value ₹11.19 lakh, saying such promoting was opposite to provisions of the Medicine and Cosmetics Act, 1940 and Medicine Guidelines, 1945.
The FDA subsequently directed the corporate to recall the misbranded Reactin Plus Tablets from the market. Nevertheless, the corporate did not absolutely adjust to the instructions and required measures, the regulator said.
A subsequent inspection of the C&F unit’s drug sale and distribution system discovered deficiencies in storage preparations, discrepancies between buy and sale information and precise computerised inventory, and non-compliance with recall instructions, in response to the assertion.
The FDA additionally discovered discrepancies between bodily inventory and computerised information, medicines saved straight on the ground, insufficient pallet and rack preparations, and deficiencies in information and procedures for dealing with expired medicines.
The division issued a show-cause discover to the licence holder. After analyzing the corporate’s rationalization, the FDA discovered that the deficiencies and instructions regarding the recall of Reactin Plus Tablets had not been adequately complied with.
FDA Commissioner Tukaram Mundhe stated the division wouldn’t present any leniency on points regarding drug security and public well being, significantly within the promoting, sale, storage and distribution of Schedule H prescription medicines.
“Any violation of guidelines by any entity concerned within the manufacture and distribution of medicines will invite strict motion as per legislation,” he stated.
Revealed – August 28, 2026 07:00 pm IST
